Eli Lilly and Co reports results for the quarter ended December 31 - Earnings Summary

• Eli Lilly and Co LLY.N reported quarterly adjusted earnings of $5.32​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $2.49. The mean expectation of eighteen analysts for the quarter was for earnings of $4.95 per share. Wall Street expected results to range from $4.68 to $5.21 per share.

• Revenue rose 44.7% to $13.53 billion from a year ago; analysts expected $13.57 billion.

• Eli Lilly and Co's reported EPS for the quarter was $4.88​.

• The company reported quarterly net income of $4.41 billion.

• Eli Lilly and Co shares had risen by 9.1% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 10.4% in the last three months.​

• In the last 30 days, thirteen analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 22 "strong buy" or "buy," 7 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Eli Lilly and Co is $997.00

This summary was machine generated from LSEG data February 6 at 02:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)